Control Resonant has already been called Remedy's fastest-selling game. Its first earnings report now shows what that meant for the studio itself: a quarter in operating profit, a year after an operating loss of €16.4 million in the same period.
Remedy published its business review for January to September on November 3. Xarmo hasn't checked that report directly, so the figures below are as reported by Inven Global and Push Square.
Revenue up 226%, and a profit
According to Inven Global, Remedy's revenue for July to September 2026 was €39.6 million, up 226% from €12.2 million a year earlier. Operating profit was €0.6 million, against an operating loss of €16.4 million in the same quarter of 2025, and EBITDA rose to €6.8 million from €0.7 million.
Push Square, which says it is working from the same business review via Eurogamer, also reports the 226% year-on-year rise and the swing from a €16.4 million loss to a €0.6 million operating profit.
Inven Global breaks the quarter down further. Game sales and royalties made up €35.3 million. A further €4.3 million came from development fees for the Max Payne 1&2 remake Remedy is making for Rockstar Games, and from the final Control Resonant fee accrual under its deal with Annapurna Pictures.
The detail that matters most for reading those numbers: Inven Global reports that only pre-orders and the first seven days of Control Resonant's sales fall inside the quarter. The game launched digitally on September 24, and the quarter closed on September 30.
Where it sold
Both outlets report that the US accounted for nearly half of sales on PC and consoles, and that close to half of players were new to Control. Inven Global adds that Chinese-speaking regions and the UK ranked second and third on PC, that Brazil made the top three by console units, and that 2.4 million wishlists remain outstanding.
The million-copy milestone itself came on October 15. PC Gamer reported at the time that Remedy called Control Resonant "the fastest-selling game in Remedy Entertainment's 31-year history", passing Alan Wake 2, which PC Gamer says took two months to sell a million copies. Inven Global reports that October 15 was also the day of the game's physical release.
The year so far
For the first nine months of 2026, Inven Global reports revenue up 48.2% to €62.9 million, with an operating loss of €2.3 million. Remedy kept its full-year outlook unchanged and expects 2026 revenue and EBITDA to grow from 2025.
Chief executive Jean-Charles Gaudechon, quoted by Inven Global, said the game was "praised by players and critics alike" and that "it marks a defining milestone for the company". He also said the launch was backed by "the largest marketing investment in our history", and that sales over the rest of the year will define Remedy's 2026.
Inven Global also reports that Remedy has a new self-published project in production readiness, and that the Max Payne 1&2 remake is in full production.
Mason's take: The profit is thin, but that isn't really the point. PC Gamer noted in October that Alan Wake 2 took more than a year to start making money for Remedy. Control Resonant, with one week of sales in the books and help from the Max Payne and Annapurna fees, returned Remedy to an operating profit for the quarter, on a game it published itself. The nine months are still in the red, so this is a start, not a turnaround. Nearly half of players being new to Control matters more than any single quarter: it suggests Remedy's odd, expensive style of game can find a bigger audience when the studio owns the launch. The fourth quarter, with the full holiday window, will show whether that holds.
Reporting notes
